Fenoldopam Treatment Improves Peripheral Insulin Sensitivity and Renal Function in STZ‐Induced Type 2 Diabetic Rats

References

• Levin B. E. Glucose‐regulated dopamine release from substantia nigra neurons. Brain Res 2000; 874(2)158–164
   PubMed Web of Science ®Google Scholar
• Saller C. F. Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 1984; 49(3)301–306
   PubMed Web of Science ®Google Scholar
• Figlewicz D. P., Brot M. D., McCall A. L., Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996; 736(1–2)54–60
   PubMed Web of Science ®Google Scholar
• Lim D. K., Lee K. M., Ho I. K. Changes in the central dopaminergic systems in the streptozotocin‐induced diabetic rats. Arch Pharm Res 1994; 17(6)398–404
   PubMedGoogle Scholar
• Segers O., Dupont A. G., Gerlo E., Somers G. Decreased urinary dopamine excretion and disturbed dopamine/sodium relationship in type 1 diabetes mellitus. Diabetes Med 1995; 12(3)229–234
   PubMed Web of Science ®Google Scholar
• Segers O., Dupont A. G., Gerlo E., Somers G. Urinary sodium and dopamine excretion: role of hyperinsulinemia in dopamine production. Med Sci Res 1996; 24: 72–73
   Google Scholar
• Hussain T., Beheray S. A., Lokhandwala M. F. Defective dopamine receptor function in proximal tubules of obese Zucker rats. Hypertension 1999; 34: 1091–1096
   PubMed Web of Science ®Google Scholar
• Umrani D. N., Hussain T., Lokhandwala M. F. Rosiglitazone treatment restores renal dopamine receptor function and lowers blood pressure in obese Zucker rats. Am J Hypertension 2002; 15: 188A
   Google Scholar
• Liang Y., Lubkin M., Sheng H., Scislowski P. W., Cincotta H. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1998; 1405(1–3)1–13
   PubMed Web of Science ®Google Scholar
• Cincotta A. H., Tozzo E., Scislowski P. W. Bromocriptine/SKF 38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61(10)951–956
   PubMed Web of Science ®Google Scholar
• Cincotta A. H., Meier A. H., Cincotta M., Jr. Bromocriptine improves glycemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Invest Drugs 1999; 8(10)1683–1707
   PubMedGoogle Scholar
• Scislowski P. W., Tozzo E., Zhang Y., Phaneuf S., Prevelige R., Cincotta A. H. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes 1999; 23: 425–431
   PubMed Web of Science ®Google Scholar
• Liang Y., Jetton T. L., Lubkin M., Meier A. H., Cincotta A. H. Bromocriptine/SKF 38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998; 54(7)703–711
   PubMed Web of Science ®Google Scholar
• Umrani D. N., Goyal R. K. Beneficial effects of fenoldopam treatment on renal function in streptozotocin‐induced diabetic rats. Clin Exp Hypertension 2002; 24(3)207–219
   PubMed Web of Science ®Google Scholar
• Bonnevie‐Nielsen V., Steffes M. W., Lernmark A. A major loss in islet mass and beta cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 1981; 30: 424
   PubMed Web of Science ®Google Scholar
• Alford F. P., Martin F. I.R., Pearson M. J. The significance and interpretation of mildly abnormal oral glucose tolerance. Diabetologia 1971; 7: 173–180
   PubMed Web of Science ®Google Scholar
• Blondel O., Bailbe D., Portha B. Relation of insulin deficiency to impaired insulin action in NIDDM adult rats given streptozotocin as neonates. Diabetes 1989; 38: 610–617
   PubMed Web of Science ®Google Scholar
• Weir G. C., Clore E. T., Zmachinsky C. J., Bonner‐Weir S. Islet secretion in a new experimental model for non‐insulin dependent diabetes. Diabetes 1981; 30: 590–595
   PubMed Web of Science ®Google Scholar
• Wang R. N., Bouwens L., Kloppel G. Beta cell growth in adolescent and adult rats treated with streptozotocin during the neonatal period. Diabetologia 1996; 39: 548–557
   PubMed Web of Science ®Google Scholar
• Bonner‐Weir S., Trent D. F., Honey R. N., Weir G. C. Responses of neonatal islets to streptozotocin: limited beta cell regeneration and hyperglycemia. Diabetes 1981; 30: 64–69
   PubMed Web of Science ®Google Scholar
• Iwase M., Nunoi K., Himeno H., Yoshinari M., Kikuchi M., Maki Y., Fugishima M. Susceptibility to neonatal streptozotocin‐induced diabetes in spontaneously hypertensive rats. Pancreas 1994; 9: 344–348
   PubMed Web of Science ®Google Scholar
• Schaffer S. W., Wilson G. L. Insulin resistance and mechanical dysfunction in hearts of wistar rats with streptozotocin‐induced non‐insulin dependent diabetes mellitus. Diabetologia 1993; 36: 195–199
   PubMed Web of Science ®Google Scholar
• Dhasmana K. M., Villalon C. M., Zhu Y. N., Parmar S. S. The role of dopamine, alpha and beta‐adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine‐related drugs in the rat. Pharmacol Res 1993; 27(4)335–347
   PubMed Web of Science ®Google Scholar
• Barthelmebs M., Vailly B., Grima M., Velly J., Stephan D., Froehly S., Imbs J. L. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin‐induced diabetes in rats. J Cardiovasc Pharmacol 1991; 18(2)243–253
   PubMed Web of Science ®Google Scholar
• Felder C. C., Campbell T., Albrecht F., Jose P. A. Dopamine inhibits Na+–H+‐exchanger activity in renal BBMV by stimulation of adenylate cyclase. Am J Physiol 1990; 259: F297–F303
   PubMed Web of Science ®Google Scholar
• Chen C. J., Lokhandwala M. F. Inhibition of Na+, K+‐ATPase in rat renal proximal tubules by dopamine involved D1‐like dopamine receptor activation. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 289–295
   PubMed Web of Science ®Google Scholar
• Cincotta A. H., Meier A. H. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricentus auratus). Metabolism 1995; 44: 1349–1355
   PubMed Web of Science ®Google Scholar
• Mann W. A., Sosnowski G. F., Kavanagh B. J., Erickson R. W., Brennan F. J., Wjebelhaus V. D. Comparative properties of two benzazepine renal vasodilator compounds: SKF 38393‐C and SKF 82526‐J. Fed Proc 1981; 40: 647
   Google Scholar
• Ackerman D. M., Weinstock J., Weibelhaus V. D., Berkowitz B. Renal vasodilators and hypertension. Drug Dev Res 1982; 2: 283–297
   Web of Science ®Google Scholar
• Feldt‐Rasmussen B., Mathiesen E. R., Deckert T., Geise J., Christersen N. J., Bent‐Hansen L., Nielsen M. D. Central role of sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone, and catecholamines in type 1 (insulin‐dependent) diabetes mellitus. Dibetologia 1987; 30: 610–617
   PubMed Web of Science ®Google Scholar